Monday, July 26

Johnson & Johnson

breakthrough cases, CDC, coronavirus, COVID-19 vaccine, Delta, Johnson & Johnson, Pfizer, Science, Symptoms, variants

You will know, or possibly be, someone who gets COVID-19 after a vaccine. Here’s what to expect, according to 2 people with breakthrough cases.

Breakthrough cases will become more common as the more transmissible Delta variant keeps spreading. But most disease experts still expect COVID-19 to be milder in vaccinated people. Two young people who got sick after they were vaccinated described how their symptoms progressed. LoadingSomething is loading. Breakthrough infections, or COVID-19 ...
coronavirus, Covid 19, janssen, Johnson & Johnson, Noticias, Salud, vacuna, Variante Delta

Janssen vaccine: “strong and resistant” to Delta variant | Digital Trends Spanish

Pharmaceutical Johnson & Johnson, parent of the Belgian company Janssen, has indicated that its vaccine against COVID-19 is effective and safe against the Delta variant. According to the laboratory, it offers an immune response that lasts for at least eight months, although it has not indicated data on the percentages of efficacy. “The studies strengthen the ability of Johnson & Johnson's COVID-19 vaccine to help protect the health of people around the world. We believe our vaccine offers long-lasting protection and neutralizing activity against the Delta variant, ”said Johnson & Johnson Chief Scientific Officer Paul Stoffels. “The data corresponding to the eight months studied so far show that the vaccine generates a strong neutralizing antibody response that does not diminish, but we...
Booster, coronavirus, Health, Healthcare, Johnson & Johnson, Science, variant

Some experts who had Johnson & Johnson’s vaccine are getting Pfizer boosters to protect against Delta — but the company says they don’t need to

A woman receives a Johnson & Johnson Covid-19 vaccine from registered nurse Gina Reed at a vaccination center established at the Hilton Chicago O'Hare Airport Hotel in Chicago, Illinois, on March 5, 2021. Kamil Krzaczynski/AFP via Getty Images Summary List Placement People that got Johnson & Johnson's single-dose COVID-19 vaccine don't need booster shots to protect against the highly infectious Delta variant, according to the company. The company said Thursday that the vaccine produced a "strong" antibody response against the Delta variant and other variants with worrisome mutations. The immune response lasted for at least eight months, they said, citing two small-scale lab experiments. The two experiments hadn't been...
AstraZeneca, booster shot, coronavirus, COVID-19 vaccine, Johnson & Johnson, Moderna, Pfizer, Science

Early findings indicate that mixing and matching coronavirus vaccines might improve your protection

The evidence in favor of a mix-and-match approach to coronavirus shots is growing.Early data from a UK study, though not yet been peer reviewed, indicates that mixing the Pfizer and AstraZeneca vaccines yields a greater immune response than two doses of AstraZeneca's shot. The researchers measured antibody levels among 830 volunteers who received either two doses of the same vaccine or a combination of Pfizer and AstraZeneca, four weeks apart.Volunteers who got AstraZeneca's shot followed by Pfizer's showed nearly the same antibody levels — and an even higher number of T-cells — as those who'd received two doses of Pfizer. By contrast, volunteers who got Pfizer's shot first and AstraZeneca's second had slightly lower antibody...
BioNTech, coronavirus, Delta, Health, Healthcare, Johnson & Johnson, Moderna, mRNA, Pfizer, Science, Vaccine, variant

Some experts who had Johnson & Johnson’s single-dose vaccine are now getting extra shots of Pfizer or Moderna to try to protect against the Delta variant

Some experts who got Johnson & Johnson's one-dose vaccine are topping it up with a dose of Pfizer or Moderna. They did it for extra protection against the fast-spreading Delta coronavirus variant, they said. The FDA and CDC don't recommend getting an extra shot, after a J&J vaccine or otherwise. LoadingSomething is loading. ...
Healthcare, Johnson & Johnson, Letitia James, New York, Opioid, weekend BI US

Johnson & Johnson will stop selling opioids in the US as part of $230 million settlement in New York

Pharmaceutical giant Johnson & Johnson will no longer sell opioids in the US as part of a $230 million settlement with the state of New York. According to the Wall Street Journal, the settlement was reached just days before the case was set to go to trial Tuesday on Long Island. The settlement does not impact the numerous other lawsuits the company faces in other states across the US from state and local governments who allege Johnson & Johnson and other pharmaceutical companies helped create the opioid epidemic.More than half a million people died from opioid use in the two decades between 1999 and 2019, according to data from the Centers for Disease Control and Prevention. ...
Aetna, Alphabet, Amazon, anthem, Apple, BI Intelligence, BI Intelligence Content Marketing, BI Intelligence Daily Conversion Series, Bright health, Chase, Cleveland Clinic, Clover Health, Comcast, CVS, Digital Health, Express Scripts, fitbit, GE Healthcare, Google, GSK, Health, IBM, Insider Intelligence, Johnson & Johnson, McKesson, MD Live, Merck, Microsoft, Oscar Health, Pfizer, Rite Aid, Samsung, Science, T-Mobile, Teladoc, UnitedHealth, Walgreens, Walmart, ZocDoc

THE DIGITAL HEALTH ECOSYSTEM: Where players across the ecosystem stand on digital transformation and what healthcare’s new normal looks like

Healthcare incumbents have been slow to adop digital transformation, but the coronavirus pandemic forced them to accelerate. The pandemic kickstarted a boom period for virtual care that is changing the way doctors and patients interact. The Digital Health Ecosystem, previewed below, analyzes the future of the healthcare industry. You can purchase this report here. Healthcare incumbents have been dragging their feet on digital transformation—but the coronavirus pandemic forced their hands to accelerate digitization and catalyzed a virtual care boom that's changing the fabric of the entire US healthcare ecosystem ...
coronavirus, Covid 19, Johnson & Johnson, Noticias, Salud

COVID-19: Promising Advances in Single-Dose Vaccine | Digital Trends Spanish

The Johnson & Johnson company announced the start of human testing of a single-dose vaccine to combat the SARS-CoV-2 virus. The decision was communicated on July 30, after the firm presented the results of a study in non-human primates that revealed that the antidote offers protection with just one dose. The study, published in the journal Nature, was performed on animals that were exposed to the virus: 32 received one of the seven candidate vaccines and another 20 were subjected to a placebo. Of the six non-human primates that received a dose of the Ad26 vaccine, which showed the best results, all were fully protected against lung disease; and five against infection. The vaccine gets its name because it uses a common cold virus, known as adenovirus type 26 or Ad26, to...